Philip Needleman

Q: What Schools Are Affiliated With Philip Needleman

Philip Needleman is affiliated with the following schools: Washington University in St. Louis, Royal Postgraduate Medical School, University of Chicago, University of the Sciences

Philip Needleman's AcademicInfluence.com Rankings

Philip Needleman

Medical

#530

World Rank

#718

Historical Rank

#204

USA Rank

Pharmacology

#42

World Rank

#57

Historical Rank

#18

USA Rank

medical Degrees

Download Badge

Medical

Philip Needleman's Degrees

Bachelors Chemistry University of Chicago

Why Is Philip Needleman Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Philip Needleman is an American pharmacologist and academic. Needleman was a professor and associate dean at the Washington University School of Medicine and he served as an executive at Monsanto/Searle. He is credited with discovering the first thromboxane synthase inhibitor, the inflammatory substance known as COX-2 and the cardiac hormone known as atriopeptin. Needleman is a member of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences.

(See a Problem?)

Philip Needleman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Nitric oxide activates cyclooxygenase enzymes. (1993) (1423)
Arachidonic acid metabolism. (1986) (1379)
The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. (1990) (918)
Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. (1979) (793)
Bioactive cardiac substances: potent vasorelaxant activity in mammalian atria. (1983) (698)
Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides (1976) (517)
Mechanism of tolerance development to organic nitrates. (1973) (511)
Purification and sequence analysis of bioactive atrial peptides (atriopeptins). (1984) (499)
Atriopeptin: a cardiac hormone intimately involved in fluid, electrolyte, and blood-pressure homeostasis. (1986) (490)
Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. (1992) (466)
Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. (1990) (413)
Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). (1988) (411)
Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. (1988) (382)
Atriopeptins as cardiac hormones. (1985) (379)
Thromboxanes: selective biosynthesis and distinct biological properties. (1976) (356)
Atriopeptin-immunoreactive neurons in the brain: presence in cardiovascular regulatory areas. (1985) (353)
Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. (1994) (318)
Vasopressin-stimulated release of atriopeptin: endocrine antagonists in fluid homeostasis. (1985) (315)
Imidazole: a selective inhibitor of thromboxane synthetase. (1977) (301)
The discovery and function of COX-2. (1997) (297)
Ser-Leu-Arg-Arg-atriopeptin III: the major circulating form of atrial peptide. (1985) (278)
Sulfhydryl requirement for relaxation of vascular smooth muscle. (1973) (264)
Cyclic adenosine 3',5'-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions. (1977) (260)
Coronary tone modulation: formation and actions of prostaglandins, endoperoxides, and thromboxanes. (1977) (250)
Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors. (1995) (235)
Organic nitrates: relationship between biotransformation and rational angina pectoris therapy. (1972) (226)
Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. (1989) (216)
Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets. (1977) (211)
Stimulation of Prostaglandin Biosynthesis by Adenine Nucleotides: Profile of Prostaglandin Release by Perfused Organs (1974) (211)
Modulation of keratinocyte proliferation in vitro by endogenous prostaglandin synthesis. (1986) (203)
Unmasking of thromboxane A2 synthesis by ureteral obstruction in the rabbit kidney (1977) (198)
Platelet and blood vessel arachidonate metabolism and interactions. (1979) (180)
Calcium-dependent norepinephrine release from presynaptic nerve endings in vitro. (1972) (177)
The biochemical pharmacology of atrial peptides. (1989) (171)
Cardiac and renal prostaglandin I2. Biosynthesis and biological effects in isolated perfused rabbit tissues. (1978) (168)
Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. (1976) (166)
Cardiac and coronary prostaglandin synthesis and function. (1978) (165)
Hormone Interactions in the Isolated Rabbit Heart: SYNTHESIS AND CORONARY VASOMOTOR EFFECTS OF PROSTAGLANDINS, ANGIOTENSIN, AND BRADYKININ (1975) (162)
Ventricular atriopeptin. Unmasking of messenger RNA and peptide synthesis by hypertrophy or dexamethasone. (1987) (153)
Exaggerated prostaglandin biosynthesis and its influence on renal resistance in the isolated hydronephrotic rabbit kidney. (1977) (153)
Atriopeptins: a family of potent biologically active peptides derived from mammalian atria. (1984) (150)
Blood vessel-hormone interactions: angiotensin, bradykinin, and prostaglandins. (1977) (147)
Exaggerated human vascular cell prostaglandin biosynthesis mediated by monocytes: role of monokines and interleukin 1. (1985) (142)
Release of atriopeptin in the rat by vasoconstrictors or water immersion correlates with changes in right atrial pressure. (1985) (140)
Thromboxane A2 biosynthesis in the ureter obstructed isolated perfused kidney of the rabbit. (1978) (139)
Manipulation of platelet aggregation by prostaglandins and their fatty acid precursors: pharmacological basis for a therapeutic approach. (1980) (135)
Activation of vagal depressor reflexes by atriopeptins inhibits renal sympathetic nerve activity. (1986) (132)
An atrial peptide is a potent renal vasodilator substance. (1984) (130)
Hormone selective lipase activation in the isolated rabbit heart. (1977) (128)
Developmental changes in the rat atriopeptin hormonal system. (1987) (127)
In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages. (1994) (126)
Effects of endogenously produced leukotrienes, thromboxane, and prostaglandins on coronary vascular resistance in rabbit myocardial infarction. (1985) (125)
Tolerance to the vascular effects of glyceryl trinitrate. (1970) (124)
Triene prostaglandins: prostaglandin D3 and icosapentaenoic acid as potential antithrombotic substances. (1979) (118)
Inhibition of the firing of vasopressin neurons by atriopeptin (1987) (114)
Paradoxical endogenous synthesis of a coronary dilating substance from arachidonate. (1976) (111)
Release of renal prostaglandin by catecholamines: relationship to renal endocrine function. (1974) (110)
Paradoxical conservation of cardiac and renal arachidonate content in essential fatty acid deficiency. (1985) (109)
Metabolic and cellular alterations underlying the exaggerated renal prostaglandin and thromboxane synthesis in ureter obstruction in rabbits. Inflammatory response involving fibroblasts and mononuclear cells. (1983) (106)
Inhibition of Aldosterone Biosynthesis by Atriopeptins in Rat Adrenal Cells (1985) (106)
Regional localization of prostacyclin and thromboxane synthesis in dog stomach and intestinal tract. (1979) (105)
The transformation of glyceryl trinitrate and other nitrates by glutathione-organic nitrate reductase. (1965) (104)
Brain natriuretic peptides: Differential localization of a new family of neuropeptides (1989) (104)
Hormonal stimulation of arachidonate release from isolated perfused organs. Relationship to prostaglandin biosynthesis. (1977) (100)
Endoperoxides and thromboxanes. Structural determinants for platelet aggregation and vasoconstriction. (1977) (99)
Characterization of a novel metabolic pathway of arachidonate in coronary arteries which generates a potent endogenous coronary vasodilator. (1977) (96)
Organic nitrate metabolism. (1976) (89)
The synthesis and function of prostaglandins in the heart. (1976) (88)
Calcium ionophore enables soluble agonists to stimulate macrophage 5-lipoxygenase. (1985) (87)
Atriopeptins: renal-specific vasodilators in conscious dogs. (1985) (86)
Specific stimulation and inhibition of renal prostaglandin release by angiotensin analogs. (1973) (86)
A novel prostaglandin is the major product of arachidonic acid metabolism in rabbit heart. (1977) (85)
Relationship between glutathione-dependent dentration and the vasodilator effectiveness of organic nitrates. (1969) (83)
Comparative Vascular Pharmacology of the Atriopeptins (1985) (81)
Novel, selective Δ6 or Δ5 fatty acid desaturase inhibitors as antiinflammatory agents in mice (2007) (80)
Relationship of prostaglandin secretion by rabbit alveolar macrophages to phagocytosis and lysosomal enzyme release. (1979) (79)
The functional significance of the regulation of macrophage Ia expression by endogenous arachidonate metabolites in vitro. (1986) (77)
Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. (2002) (77)
Profile of circulating vasoactive substances in hemorrhagic shock and their pharmacologic manipulation. (1974) (76)
Stretch-induced atriopeptin secretion in the isolated rat myocyte and its negative modulation by calcium. (1989) (76)
Distribution of glucose and related metabolites in rat kidney. (1968) (74)
Mechanism and modification of bradykinin-induced coronary vasodilation. (1975) (73)
Atriopeptin turnover: quantitative relationship between in vivo changes in plasma levels and atrial content. (1986) (73)
Selective incorporation of 14C-arachidonic acid into the phospholipids of intact tissues and subsequent metabolism to 14C-prostaglandins. (1976) (73)
Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure. (1990) (71)
Synthesis of prostaglandins by cultured rat hearts myocytes and cardiac mesenchymal cells. (1980) (69)
Fluorescent derivatives of prostaglandins and thromboxanes for liquid chromatography. (1978) (69)
Dihomo-prostaglandins and -thromboxane. A prostaglandin family from adrenic acid that may be preferentially synthesized in the kidney. (1982) (68)
Relationship between oxygen tension, coronary vasodilation and prostaglandin biosynthesis in the isolated rabbit heart. (1975) (68)
Fatty acid structural requirements for leukotriene biosynthesis. (1980) (67)
Specific regulation of peptide-induced renal prostaglandin synthesis. (1979) (67)
Evidence for Two Distinct Forms of Fatty Acid Cyclooxygenase in Brain (1982) (67)
Renal arachidonic acid metabolism. (1984) (67)
Mechanism of enhanced fibroblast arachidonic acid metabolism by mononuclear cell factor. (1984) (66)
Development, validation and application of an enzyme immunoassay (EIA) of atriopeptin. (1987) (64)
A mechanism for the hydroperoxide-mediated inactivation of prostacyclin synthetase. (1979) (64)
Prostaglandin release by the isolated perfused rabbit heart. (1973) (62)
The biotransformation of nitroglycerin. (1965) (61)
Exaggerated Prostaglandin and Thromboxane Synthesis in the Rabbit with Renal Vein Constriction (1980) (60)
Proteolytic processing of atriopeptin prohormone. (1986) (59)
Characterization of central angiotensin II receptors involved in the elicitation of drinking in the rat. (1973) (58)
Inactivation of vascular prostacyclin synthetase by platelet lipoxygenase products. (1980) (58)
Differential biosynthesis of prostaglandins by hydronephrotic rabbit and cat kidneys. (1981) (57)
Reversible induction of right ventricular atriopeptin synthesis in hypertrophy due to hypoxia. (1988) (56)
Mechanism of enhanced renal prostaglandin biosynthesis in ureter obstruction. Role of de novo protein synthesis. (1978) (56)
Stimulation of renal prostaglandin synthesis by the pressor activity of vasopressin. (1981) (54)
Sites of lipase activation and prostaglandin synthesis in isolated, perfused rabbit hearts and hydronephrotic kidneys (1978) (54)
Atriopeptin release from the isolated perfused rabbit heart. (1984) (54)
Contribution of Thromboxane to Renal Resistance Changes in the Isolated Perfused Hydronephrotic Rabbit Kidney (1982) (53)
Brain natriuretic peptide-like immunoreactive innervation of the cardiovascular and cerebrovascular systems in the rat. (1990) (53)
Thromboxane synthase is preferentially conserved in activated mouse peritoneal macrophages. (1985) (52)
Novel, selective delta6 or delta5 fatty acid desaturase inhibitors as antiinflammatory agents in mice. (1999) (52)
Metabolic and functional alterations in macrophages induced by essential fatty acid deficiency. (1987) (52)
Is atriopeptin a physiological or pathophysiological substance? Studies in the autoimmune rat. (1988) (52)
Kallikrein activation of a high molecular weight atrial peptide. (1984) (50)
Non‐steroidal anti‐inflammatory drug‐induced renal failure: a brief review of the of cyclo‐oxygenase isoforms (1998) (48)
Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3',5'-cyclic monophosphate degradation. (1990) (48)
Renal concentrations of prostaglandin E in acute and chronic renal ischemia. (1972) (48)
Identification and Characterization of a Novel Δ6/Δ5 Fatty Acid Desaturase Inhibitor As a Potential Anti-Inflammatory Agent (1998) (48)
Thromboxane synthetase inhibitors as pharmacological tools: differential biochemical and biological effects on platelet suspensions. (1977) (47)
Atriopeptins: correlation between renal vasodilation and natriuresis. (1985) (47)
The metabolic pathway in the degradation of glyceryl trinitrate. (1971) (47)
Autoradiographic localization of atriopeptin III receptors in rat kidney. (1985) (46)
The sequence of an atriopeptigen: a precursor of the bioactive atrial peptides. (1984) (45)
Effects of atriopeptin infusion versus effects of left atrial stretch in awake dogs. (1986) (44)
Mechanisms Underlying Atriopeptin‐Induced Increases in Hematocrit and Vascular Permeation in Rats (1989) (44)
Is the peripheral sympatho-adrenal nervous system necessary for renal hypertension? (1976) (44)
Pharmacological manipulation of cyclo‐oxygenase‐2 in the inflamed hydronephrotic kidney (1996) (44)
Atriopeptins: potential mediators of an endocrine relationship between heart and kidney (1984) (44)
Monocyte migration explains the changes in macrophage arachidonate metabolism during the immune response. (1986) (44)
Clearance and metabolism of organic nitrates. (1972) (43)
Effects of organic nitrates on mitochondrial respiration and swelling: possible correlations with the mechanism of pharmacologic action. (1966) (41)
The Arachidonic Acid Metabolic Capacity of Canine Myocardium is Increased during Healing of Acute Myocardial Infarction (1982) (41)
Determinants and modification of adrenergic and vascular resistance in the kidney. (1974) (41)
Synthesis and secretion of an atriopeptin-like protein in rat kidney cell culture. (1991) (41)
MODIFICATION OF RESPONSES TO SYMPATHETIC NERVE STIMULATION BY THE RENIN‐ANGIOTENSIN SYSTEM IN RATS (1974) (40)
The Pharmacological and Biochemical Interaction of Organic Nitrates with Sulfhydryls: Possible Correlations with the Mechanism for Tolerance Development, Vasodilation, and Mitochondrial and Enzyme Reactions (1975) (39)
Gadolinium-DTPA liposomes as a potential MRI contrast agent. Work in progress. (1988) (39)
Mechanism underlying the inhibition of platelet aggregation by eicosapentaenoic acid and its metabolites. (1980) (39)
Manipulation of stretch-induced atriopeptin prohormone release and processing in the perfused rat heart. (1988) (39)
Role of endogenous glutathione in the metabolism of glyceryl trinitrate by isolated perfused rat liver. (1971) (38)
Atriopeptin III. A potent natriuretic, diuretic, and hypotensive agent in rats with chronic renal failure. (1985) (37)
Renal synthesis of atriopeptin-like protein in physiology and pathophysiology. (1991) (36)
Fatty acids as sources of potential "magic bullets" for the modification of platelet and vascular function. (1981) (36)
Interactions between the inducible cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) pathways: implications for therapeutic intervention in osteoarthritis. (1999) (36)
Prostaglandins and the heart. (1979) (35)
Experimental criteria for evaluating prostaglandin biosynthesis and intrinsic function. (1978) (35)
Manipulation of rat brain fatty acid composition alters volatile anesthetic potency. (1986) (35)
Macrophage-dependent arachidonate metabolism in hydronephrosis. (1984) (34)
Biotransformation of Organic Nitrates (1975) (33)
Differential structure-activity relationships of atrial peptides as natriuretics and renal vasodilators in the dog. (1985) (33)
The biochemical and pharmacological manipulation of cellular cyclooxygenase (COX) activity. (1991) (32)
Temporal changes in 12-HETE formation in two models of canine myocardial infarction. (1985) (31)
Expression of the gene for preproatriopeptin in the central nervous system of the rat. (1988) (31)
Synthesis, biological activity, and 19 F nuclear magnetic resonance spectra of angiotensin II analogs containing fluorine. (1973) (31)
Localization of brain and atrial natriuretic peptide in human and porcine heart. (1992) (31)
Discovery of a better aspirin. (1995) (30)
Metabolism of and vascular responses to glyceryl trinitrate in the eviscerated rat. (1972) (30)
Nitric oxide and the cyclooxygenase pathway. (1995) (30)
Stimulation of splenic prostaglandin release by angiotensin and specific inhibition by cysteine 8-AII. (1973) (28)
Kinetic comparison and regulation of the cascade of microsomal enzymes involved in renal arachidonate and endoperoxide metabolism. (1983) (27)
Specific COX-2 inhibitors: from bench to bedside (1998) (27)
Increased renal tubular synthesis of prostaglandins in the rabbit kidney in response to ureteral obstruction. (1979) (27)
Induction of cyclo-oxygenase synthesis in human promyelocytic leukaemia (HL-60) cells during monocytic or granulocytic differentiation. (1990) (27)
Localization, synthetic regulation, and biology of renal atriopeptin-like prohormone. (1992) (27)
A novel prostaglandin 11-keto reductase found in rabbit liver. (1981) (27)
Effect of atriopeptin III on renin release in vitro. (1986) (27)
Proteolytic activation of a bioactive cardiac peptide by in vitro trypsin cleavage. (1984) (26)
NITRIC OXIDE ACTIVATES THE CYCLOOXYGENASE PATHWAY IN INFLAMMATION (1995) (26)
Long-acting angiotensin II inhibitors containing hexafluorovaline in position 8. (1987) (26)
Role of invading leukocytes in enhanced atrial eicosanoid production following rabbit left ventricular myocardial infarction. (1989) (26)
Peptide-induced prostaglandin biosynthesis in the renal-vein-constricted kidney. (1981) (25)
Prostacyclin in blood vessel–platelet interactions: perspectives and questions (1979) (25)
Prostaglandin release from vasculature by angiotensin II: dissociation from lipolysis. (1973) (25)
Effect of Endogenously Produced Leukotrienes and Thromboxane on Renal Vascular Resistance in Rabbit Hydronephrosis (1987) (25)
Angiotensin (A I, A II, A III) receptor characterization. Correlation of prostaglandin release with peptide degradation. (1977) (25)
Atriopeptin release in conditions of altered salt and water balance in the rat. (1986) (24)
Cellular confluence determines injury-induced prostaglandin E2 synthesis by human keratinocyte cultures. (1987) (24)
The metabolic transformations of columbinic acid and the effect of topical application of the major metabolites on rat skin. (1985) (24)
Indomethacin in vivo increases the sensitivity to Listeria infection in mice. A possible role for macrophage thromboxane A2 synthesis. (1987) (23)
Differential modification of cyclo-oxygenase and peroxidase activities of prostaglandin endoperoxidase synthase by proteolytic digestion and hydroperoxides. (1990) (23)
Arachidonic acid-induced platelet aggregation independent of ADP-release in a patient with a bleeding disorder due to platelet storage pool disease. (1979) (23)
Integrated cardiac and peripheral vascular response to atriopeptin 24 in conscious dogs. (1986) (23)
COX-2 Inhibitors – Is there cause for concern? (1999) (23)
Analogues of angiotensin II with restricted conformational freedom, including a new antagonist. (1976) (22)
Lipases and prostaglandin biosynthesis. (1978) (22)
Prostaglandins and the renin-angiotensin system in canine endotoxemia. (1977) (22)
Atriopeptins: volume regulatory hormones. (1985) (21)
Analogues of arachidonic acid used to evaluate structural determinants of prostaglandin receptor and enzyme specificities. (1981) (21)
Cell culture of renal epithelium derived from rabbit microdissected cortical collecting tubules. (1983) (21)
Paradoxical relationship between atriopeptin plasma levels and diuresis-natriuresis induced by acute volume expansion. (1988) (20)
Work in progress: Angiotensin III - induced prostaglandin (PG) release (1976) (20)
Arachidonic acid metabolism by rabbit fetal membranes of various gestational ages. (1984) (20)
Perfusion-dependent induction of de novo synthesis of renal phosphatide acyl hydrolase in ureter-obstructed rabbit kidney. (1980) (20)
Effect of epinephrine and potassium chloride on contraction and energy intermediates in rabbit thoracic aorta strips. (1970) (19)
Analogs of bradykinin with restricted conformational freedom. (1975) (19)
Localization of exaggerated prostaglandin synthesis associated with renal damage. (1981) (18)
Novel, selective delta6 or delta5 fatty acid desaturase inhibitors as antiinflammatory agents in mice. (1998) (18)
Characterization of the reaction sequence involved in phospholipid labeling and deacylation and prostaglandin synthesis and actions. (1978) (18)
Sulfhydryl reactivity of organic nitrates: biochemical basis for inhibition of glyceraldehyde-P dehydrogenase and monoamine oxidase. (1973) (18)
A unique cardiac cytosolic acyltransferase with preferential selectivity for fatty acids that form cyclooxygenase/lipoxygenase metabolites and reverse essential fatty acid deficiency. (1985) (18)
Macrophages isolated from liver granulomas of murine Schistosoma mansoni synthesize predominantly TxA2 during the acute and chronic phases of infection. (1988) (17)
Anti-inflammatories for cardiovascular disease. (2000) (17)
Inhibition of brain adenylate cyclase by ethacrynic acid and dithiobisnitrobenzoic acid. (1973) (17)
The role and manipulation of eicosanoids in essential fatty acid deficiency. (1986) (16)
Endotoxin induces chronic prostaglandin and thromboxane synthesis from ureter-obstructed kidneys: role of inflammatory cells. (1983) (16)
Regulation of prostanoids synthesis in human fibroblasts and human blood monocytes by interleukin-1, endotoxin, and glucocorticoids. (1990) (16)
Calcium-dependent oxidation of 5,8,11-icosatrienoic acid by the cyclooxygenase enzyme system. (1986) (16)
Atriopeptin: neuromediator in the central regulation of cardiovascular function (1988) (16)
Thromboxane A2Does Not Contribute to Arrhythmogenesis During Evolving Canine Myocardial Infarction (1985) (15)
Atriopeptin biochemical pharmacology. (1986) (15)
Lipid remodeling in mouse liver and plasma resulting from Δ6 fatty acid desaturase inhibition (2001) (15)
Physiology: The expanding physiological roles of atrial natriuretic factor (1986) (15)
Identification and characterization of a novel delta6/delta5 fatty acid desaturase inhibitor as a potential anti-inflammatory agent. (1998) (14)
Pharmacological manipulation of inflammation in rabbit hydronephrosis: effects of a combined cyclooxygenase/lipoxygenase inhibitor ethoxyquin, a thromboxane synthase inhibitor RS-5186 and a PAF antagonist L-659,989. (1989) (14)
Organic nitrates (1975) (14)
Physiologic effects of columbinic acid and its metabolites on rat skin. (1985) (13)
Prostaglandin production by the pregnant and non-pregnant rabbit uterus. (1983) (13)
The cell biology of fibroblast cyclooxygenase. (1989) (13)
Effect of pharmacological manipulation of endogenous atriopeptin activity on renal function. (1992) (13)
Ductus arteriosus closure may result from suppression of prostacyclin synthetase by an intrinsic hydroperoxy fatty acid. (1981) (13)
Proceedings: Formation of prostaglandin endoperoxides and rabbit aorta contracting substance (RCS) by coupling two enzyme systems. (1976) (12)
Arachidonic acid metabolic pathways in the rabbit pericardium. (1984) (12)
The Mechanism and Site of the Enhanced Arachidonate Metabolism in Ureter Obstruction (1983) (11)
Prostaglandin synthesis by dog gastrointestinal tract. (1980) (11)
Heparin interferes with the biological effectiveness of atriopeptin. (1987) (11)
Essential fatty acid deficiency reduces the inflammatory cell invasion in rabbit hydronephrosis resulting in suppression of the exaggerated eicosanoid production. (1988) (11)
Processing of atriopeptin prohormone by nonmyocytic atrial cells. (1992) (11)
Arachidonic acid metabolic pathway of the rabbit placenta. (1985) (10)
Contents Volume 1 (1993) (10)
Autoradiographic discrimination of brain and atrial natriuretic peptide-binding sites in the rat kidney. (1991) (10)
Eicosapentaeonic acid and the triene prostaglandins: Pharmacology and therapeutic potential (1980) (10)
Essential fatty acid deficiency: a new look at an old problem. (1986) (10)
Exaggerated atrial arachidonate metabolism in rabbit left ventricular myocardial infarction. (1987) (10)
Differentiation of bradykinin receptors and of kininases with conformational analogues of bradykinin. (1978) (10)
Angiotensin II. Synthesis and biological activity of 6-(1-methylhistidine) and 6-(3-methylhistidine) analogs. (1973) (9)
Atriopeptin Expression in the Ventricle (1987) (9)
Identification of the cardiac and circulating form of atriopeptin in rabbit. (1986) (9)
Arachidonate metabolism in renal injury. (1985) (9)
Efficacy of long-acting nitrates (1976) (9)
Prostaglandin endoperoxide E2 isomerase is dissociated from prostaglandin endoperoxide synthetase in the renal cortex. (1982) (9)
Indomethacin inhibits the cellular receptor-dependent processing of low density lipoproteins; cyclic nucleotides have no effect. (1980) (8)
Regulation of macrophage arachidonic acid metabolism during the immune response. (1987) (8)
A novel cyclooxygenase metabolite of arachidonic acid. (1984) (8)
Renal arachidonic acid metabolism and cellular changes in the rabbit renal vein constricted kidney: inflammation as a common process in renal injury models. (1984) (8)
Alkylating analogs of bradykinin. (1975) (8)
Angiotensin III-induced prostaglandin (PG) release. (1976) (8)
Vasodilator properties of a family of bioactive atrial peptides in isolated perfused rat kidneys. (1985) (7)
Pharmacological manipulation of canine cyclooxygenase and thromboxane synthetase in vivo: differential renal and platelet recovery rates. (1984) (7)
Effect of Endothelial Damage on Prostaglandin Synthesis by Isolated Perfused Rabbit Mesenteric Vasculature (1979) (7)
Effects of prostacyclin on short-circuit current and water flow in the toad urinary bladder. (1983) (7)
Dissociation of sympathetic compensation from glyceryl trinitrate tolerance. (1973) (7)
Atriopeptins in fluid and electrolyte homeostasis. (1986) (7)
The IRI Medalist's Address: From a Twinkle In the Eye To a Blockbuster Drug (2001) (6)
Essential fatty acid deficiency inhibits early but not late leukocyte infiltration in rabbit myocardial infarcts. (1989) (6)
Exaggerated prostaglandin and thromboxane synthesis in the renal vein constricted rabbit. (1980) (6)
Atriopeptins: circulating volume regulatory hormones with potential therapeutic role in chronic renal failure. (1986) (6)
PGD3 is the mediator of the antiaggregatory effects of the trienoic endoperoxide PGH3. (1980) (6)
Selective inhibitors of platelet arachidonic acid metabolism: aggregation independent of lipoxygenase. (1982) (6)
Angiotensin antogonists as pharmacological tools. (1976) (5)
Stereospecific synthesis of columbinic acid (1983) (5)
Atriopeptins: bioactive peptides derived from mammalian cardiac atria. (1984) (5)
Cytokine modulation of immune activation associated suppression of macrophage cyclooxygenase activity in vivo. (1992) (5)
BIOLOGICAL AND CHEMICAL CHARACTERIZATION OF A UNIQUE ENDOGENOUS VASODILATOR PROSTAGLANDIN PRODUCED IN ISOLATED CORONARY ARTERY AND IN INTACT PERFUSED HEART (1977) (5)
Arachidonic Acid Metabolism in Tissue Injury (1988) (5)
A Potent Natriuretic, Diuretic, and Hypotensive Agent in Rats with Chronic Renal Failure (1985) (4)
Post-translational processing and secretory pathway of human atriopeptin in rat pheochromocytoma cells. (1991) (4)
Isolation and Characterization of the Complementary DNA for Sheep Seminal Vesicle Prostaglandin Endoperoxide (1988) (4)
Presence of inflammatory cells associated with exaggerated arachidonic acid metabolism in renal injury. (1983) (4)
ENDOGENOUSLY PRODUCED LEUKOTRIENES CAUSE VASOCONSTRICTION IN INFARCTED RABBIT HEARTS (1984) (4)
Prostaglandin I2 Synthesis and Vascular Effects in Isolated Coronary Artery1 (1978) (3)
Relationship between plasma atriopeptin concentration and function in the conscious primate. (1989) (3)
Origin of porcine brain natriuretic peptide-like immunoreactive innervation of the middle cerebral artery in the rat (1991) (3)
Measurement of prostaglandin biosynthetic capacity in discrete areas of the rabbit hippocampal formation (1983) (3)
A mononuclear cell factor is a potent agonist of prostaglandin biosynthesis in cultured human fibroblasts and smooth muscle and endothelial cells. (1985) (3)
Alternative mechanisms for atriopeptin prohormone processing by isolated perfused rat hearts. (1990) (3)
Sulfhydryl Reactivity of Organic Nitrates : Tolerance and Vasodilation (1976) (2)
Angiotensin-receptor interaction: influence of pH on angiotensin inhibition by Phe 4 -Tyr 8 -angiotensin II in rat uterine smooth muscle. (1972) (2)
Letter: Efficacy of long-acting nitrates. I. sublingual versus oral administration. (1976) (2)
Differentiation in vivo of the sequential blood cell invasion following ureter obstruction of the rabbit kidney. (1989) (2)
Rationale for the Suppression of Platelet Aggregation and Thrombosis by Dietary Manipulation of Fatty Acids (1981) (2)
Triene prostaglandins : Prostaglandin D 3 and icosapentaenoic acid as potential antithrombotic substances ( prostaglandin H 3 / platelets / 2 ' , 5 '-dideoxyadenosine ) (2)
Strategies for the in vivo inhibition of endogenous atriopeptin. (1988) (2)
Atrial Natriuretic Factor in Plasma of Patients with Arterial Hypertension , Heart Failure or Cirrhosis of the Liver (2)
The role of prostaglandins and thromboxane in modulation of perfusion pressure in the hydronephrotic rabbit kidney. (1980) (1)
In vivo inhibition of thromboxane synthetase in infarcted canine myocardium. (1984) (1)
Potentiation by phenobarbital of the diuretic response to chlorothiazide. (1962) (1)
Intrinsic Prostaglandin Biosynthesis in Blood Vessels (2011) (1)
Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme ( prostaglandins / macrophages / steroids / eicosanoids ) (1)
Synthesis and biological properties of selective inhibitors of the prostaglandin cascade. (1980) (1)
Complementary DNA clone for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). (1989) (1)
Cardiac and renal lipases and prostaglandin biosynthesis (1979) (1)
Cardiac and renal lipase activation and its relationship to prostaglandin (PG) synthesis (1978) (0)
Treatment and prophylaxis of radiation damage. (1961) (0)
Treatment alzheimer's disease with r(-) 2-arylproponic acid nsaid alone or in combination with selective cox-2 inhibitor (2004) (0)
Angiotensin antagonists: overview and projection. (1976) (0)
Role of Inflammatory Cells in Metabolic and Cellular Alterations Underlying the Exaggerated Renal Prostaglandin and Thromboxane Synthesis in Ureter Obstruction (1984) (0)
Prostaglandins and related compounds. Seventh International Conference. Florence, Italy. May 28-June 1, 1990. Proceedings. (1991) (0)
Biologically active peptide and peptide fragment thereof having natriuretic, diuretic and vasodilating activity and therapeutic agent containing such a peptide or peptide fragment (1985) (0)
790 – THE PERIPHERAL SYMPATHETIC NERVOUS SYSTEM IN RENAL HYPERTENSION (1977) (0)
Macrophage-dependent arachidonate metabolism in hydronephro (2010) (0)
871 – REGIONAL LOCALIZATION OF PGI2 AND THROMBOXANE SYNTHESIS IN DOG STOMACH AND INTESTINAL TRACT (1978) (0)
Induced prostaglandin E2 (PGE/sub 2/) synthesis by human keratinocyte cultures is determined by culture confluence (1986) (0)
Contents of Volume 1 (1983) (0)
Pharmacology of Antagonists of Angiotensln I and II (2005) (0)
Application ofimidazole asaselective inhibitor ofthromboxane synthetase inhumanplatelets (prostaglandin/endoperoxides/arachidonate/aggregation/vasoconstrictor) (1977) (0)
ALKYLATING ANALOGS OF BRADYKININ (1976) (0)
Manipulation ofstretch-induced atriopeptin prohormone release andprocessing intheperfused ratheart (atrial natriuretic factor/atrial stretch/cleavage) (1988) (0)
ANGIOTENSIN PART 2, SYNTHESIS AND BIOLOGICAL ACTIVITY OF 6-(1-METHYLHISTIDINE) AND 6-(3-METHYLHISTIDINE) ANALOGS (1973) (0)
Biological and molecular aspects of atrial factors : proceedings of a director's sponsors-UCLA symposium held at Steamboat Springs, Colorado, January 17-23, 1988 (1988) (0)
Erratum (1976) (0)
Mechanism of atriopeptin release in isolated myocytes (1987) (0)
The influence of atriopeptin on renal function. (1985) (0)
1587 ATRIOPEPTIN: A POWERFUL NATRIURETIC IN RATS WITH RENAL FAILURE (1985) (0)
ANALOGS OF BRADYKININ WITH RESTRICTED CONFORMATIONAL FREEDOM (1976) (0)
ATRIOPEPTINS: NATRIURESIS OCCURS INDEPENDENT OF VASCULAR EFFECTS (1984) (0)
Atriopcptin: Discoveries and Implications (1988) (0)
Enhanced thromboxane synthesis in atria from infarcted rabbit hearts (1986) (0)
Radioimmunoassay of Atrial Peptide Blood and Tissue Levels (1987) (0)
Hormone regulation of prostaglandin synthesis in the heart (1976) (0)
The induction of thromboxane synthetase as an expression of renal pathology (1981) (0)
Regulation ofprostaglandin production bynitric oxide; an in (1995) (0)
Current concepts of the mode of action of salicylates in rheumatic diseases. (1961) (0)
MANIPULATION OF RAT BRAIN LIPID COMPOSITION ALTERS VOLATILE ANESTHETIC POTENCY (1985) (0)
Indium labelled leukocytes as markers of inflammatory cellular changes in hydronephrosis (1984) (0)

This paper list is powered by the following services:

Other Resources About Philip Needleman

en.wikipedia.org

What Schools Are Affiliated With Philip Needleman?

Philip Needleman is affiliated with the following schools:

Philip Needleman's Academic­Influence.com Rankings